胰岛素在急性ST段升高心肌梗塞中具有抗炎和益氨解作用
Ajay Chaudhuri1, David Janicke, Michael F Wilson
1Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, NY 14209, USA.
Circulation
|February 6, 2004
概括
在ST段升高心肌梗塞 (STEMI) 患者中,胰岛素的使用显示出显著的抗炎和益发解作用. 这些发现表明胰岛素胰岛素.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素在急性ST段升高心肌梗塞 (STEMI) 的临床益处可能涉及抗炎机制.
- 这项研究研究了胰岛素在接受纤维解药治疗的STEMI患者的抗炎潜力.
研究的目的:
- 评估胰岛素在患有急性ST段升高心肌梗塞 (STEMI) 的患者中的抗炎和益氨解效应.
主要方法:
- 32名接受Reteplase治疗的STEMI患者随机分配,接受胰岛素,乳糖和 (GIK) 或正常盐水和 (对照组) 48小时.
- 血炎症标志物 (高灵敏度C-反应蛋白,血清粉样蛋白A) 和凝血 (血原激活剂抑制剂-1) 被测量顺序测量.
- 单核细胞p47phox蛋白水平在一个子组中进行了评估.
主要成果:
- 与对照人群相比,胰岛素治疗在24小时和48小时内显著减轻了血清C反应蛋白 (CRP) 和血清粉样蛋白A (SAA) 的上升,分别为40%和50%,与对照人群相比.
- 胰岛素显著降低了血原激活剂抑制剂-1 (PAI-1) 和p47phox蛋白水平的增加.
- 肌酸激酶-MB (CK-MB) 较早达到峰值,在胰岛素组倾向于较低,特别是在较低的MI病例中.
结论:
- 胰岛素在急性心肌梗塞 (MI) 患者中表现出抗炎和益肌解质性质.
- 这些观察到的胰岛素效应可能有助于其在STEMI管理中的临床益处.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
905
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
905
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Myocarditis I: Introduction
612
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
612
Myocarditis III: Medical Management
327
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Acute Coronary Syndrome I: Introduction
1.8K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K
Acute Coronary Syndrome IV: Interprofessional Care
490
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
490


